QuilliChew Extended-release Chewable Tablets for the Treatment of ADHD in Patients Ages 6 Years Old and Above

Document Type

Article

Publication Date

11-15-2018

Publication Title

Expert Opinion on Drug Delivery

Volume

15

Issue

12

First page number:

1263

Last page number:

1270

Abstract

Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder affecting as many as 6.4 million children and adolescents in the United States. Since amphetamine (AMPH) and methylphenidate (MPH) were found to be effective more than 60 years ago, numerous formulations of these compounds have been developed. New preparations have focused on convenience, with extended-release (ER) drugs allowing once-daily dosing. Multiple ER formulations do not require patients to swallow a tablet or capsule. Recent ER preparations include liquids, oral disintegrating tablets, and chewable tablets. Several new formulations use ion exchange technology containing both immediate-release and ER components. Areas covered: Quillichew ERTM (MPH-ERCT) is an ER methylphenidate designed to be chewed before swallowing. The technology and pharmacokinetics, along with efficacy and safety data, are presented. Expert opinion: Extensive safety and efficacy data exist for MPH. ER formulations can be distinguished by preparation (tablet, capsule, liquid) and onset and duration of effect, but efficacy is similar for all ER MPH products. Each formulation has attributes, such as ease of titration, portability, and taste, that make it more acceptable for certain patients. Because AMPH and MPH are so effective, current technology research is focused on improving safety, convenience, and onset and duration of effect.

Keywords

Attention-deficit/hyperactivity disorder; ADHD; Methylphenidate; Quillichew ER

Disciplines

Pharmacy and Pharmaceutical Sciences

Language

English

UNLV article access

Search your library

Share

COinS